Catalyst
Slingshot members are tracking this event:
Cocrystal Pharma Receives Health Canada Approval to Conduct Phase I Clinical Study for CC-31244 in Healthy and HCV-Infected Subjects
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| COCP | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 25, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Cc-31244, Health Canada, Approval, Hcv, Pan-genotypic, Potent Ns5b, Non-nucleoside Inhibitor, Nni, Chronic Hepatitis C Virus
